Benzodiazepine Withdrawal Symptom Clusters: Distinct Phenotypes with Treatment Implications

Valsa Madhava, MD, MPH, MS

Independent Clinical Researcher, The Benzo Taper Doctor, New York, USA
Associate Staff, Department of General Internal Medicine, Mount Sinai Health System, New York, NY, USA
Attending, Medicine/Behavioral Health Services, St. John's Riverside Hospital, Yonkers, NY, USA

Corresponding Author
Valsa S. Madhava, MD, MPH, MS
Email: vmadhava@thebenzotaperdoctor.com

Abstract

Background: Benzodiazepine withdrawal is highly heterogeneous, ranging from mild, transient symptoms to a severe, protracted syndrome. Existing descriptive approaches catalog symptoms without explaining the underlying biology, which often makes the tapering schedule the sole focus of management—an approach that provides only partial relief.

Methods: Baseline data from 39 patients in a specialty taper program were analyzed. To assign phenotypes, symptoms reported in a comprehensive 233-item questionnaire were mapped onto five pre-specified mechanistic axes reflecting neurobiological and immune pathways.

Results: Most patients (79.5%) clustered into one of three phenotypes: corticotropin-releasing hormone (CRH)–heavy (35.9%), excitatory–neuroinflammatory (ENI) (33.3%), or Autonomic (10.3%). The remaining patients were classified as Low-symptom (17.9%) or Mixed (2.6%); no patients were classified as Basal Ganglia–Cerebellar (BG/Cer). Features consistent with mast cell activation (MCAS-overlap) were observed in just over half of the cohort (53.8%). PROMIS-29 scores demonstrated severe, multi-domain functional impairment, with notably elevated T-scores in Anxiety and Fatigue.

Conclusion: Benzodiazepine withdrawal is not a unitary syndrome but clusters into reproducible, biologically grounded phenotypes. Notably, nearly 80% of patients in this cohort fell into just three of these phenotypes, suggesting that withdrawal, though heterogeneous, may follow structured and predictable patterns. Recognizing these patterns enables clinicians to anticipate vulnerabilities and personalize management, shifting the therapeutic goal from merely executing a taper to stabilizing the underlying neurobiology.

Introduction

Despite their widespread use, the long-term prescription of benzodiazepines and their subsequent discontinuation present substantial clinical challenges. Withdrawal syndromes can be protracted, severe, and highly heterogeneous, with symptoms spanning the psychiatric, neurological, autonomic, gastrointestinal, and sensory domains. Patients and clinicians have long noted this variability, which is documented in advocacy resources such as Benzoinfo.com and in large patient surveys (1,2)

The descriptive construct of benzodiazepine-induced neurological dysfunction (BIND) has been proposed to capture the persistence and breadth of sequelae better following benzodiazepine use. While valuable for emphasizing that withdrawal extends beyond short-term rebound anxiety, BIND remains descriptive and does not provide a framework for the underlying biological mechanisms. Extensive work on $GABA_A$ receptor adaptations, tolerance, and circuit-level changes provides a neurobiological context for this heterogeneity (3–5).

Building on this foundation, the specialty taper program described here operates within a systems-based clinical framework, emphasizing patient-centered care supported by structured intake questionnaires. From the outset, it was evident that tapering alone was rarely sufficient to resolve the broad range of withdrawal symptoms; effective management required concurrent supportive measures such as nutritional interventions, supplementation, stress management, and judicious use of medications. To guide these interventions, a comprehensive baseline assessment—both quantitative and qualitative—was undertaken to evaluate each patient's symptom burden and functional status. Shortly after the program's launch, a structured 233-item questionnaire was developed to capture the full scope of withdrawal manifestations. This tool served as the primary instrument for phenotyping and provided a standardized framework for documenting patient experiences.

The questionnaire was complemented by other baseline forms, including an Adverse Childhood Experiences (ACE) questionnaire, a nutrient deficiency questionnaire, and a 3-day diet diary. Standardized intake measures, such as the Patient-Reported Outcomes Measurement Information System (PROMIS) Profile v2.0 (PROMIS-29) (6) were also administered to provide standardized measures of functional status.

Analysis of the 233-item symptom questionnaire revealed reproducible patterns that suggested the presence of distinct mechanistic phenotypes rather than a unitary syndrome. Based on these patterns, clinical presentations were mapped onto several candidate mechanisms, including dysregulation of the corticotropin-releasing hormone (CRH)/adrenergic (stress) axis; excitatory–inhibitory imbalance with associated neuroinflammation; autonomic dysfunction; basal ganglia–cerebellar involvement; and broader systemic immune dysregulation. Here, observational findings from 39 patients are presented, focusing on the 233-item questionnaire and PROMIS-29, with the aim of delineating candidate withdrawal phenotypes anchored in plausible neurobiological and immunological mechanisms. This approach moves beyond a descriptive catalog of symptoms and provides a framework to explain clinical heterogeneity and inform mechanism-based management strategies.

Methods

Clinical Setting and Cohort

This study analyzed observational data from 39 consecutive patients enrolled in a specialty benzodiazepine taper program. The program's protocol emphasizes comprehensive baseline assessment and individualized management strategies, as described in the Introduction. Thirty-seven of the 39 patients presented with the intent to begin a supervised taper; two were post-taper but remained symptomatic. All patients received baseline laboratory testing to guide safety monitoring and inform nutritional and supplemental interventions. A subset also underwent advanced integrative testing based on patient preference and practitioner recommendation. For the present analysis, which focuses on symptom clustering and functional status, data from the 233-item symptom questionnaire and the PROMIS-29 questionnaire were utilized. These data were collected alongside standard medical and substance use histories during the structured intake process. Data from additional baseline forms (e.g., diet diary, ACE questionnaire) were used for clinical management and are not analyzed in this study. Findings from these comprehensive assessment tools guided clinical decision-making, including taper initiation and supportive interventions.

Data Collection and Instruments

Symptom Questionnaire Construction

A 233-item symptom questionnaire was constructed in 2023 by adapting nearly verbatim the "Withdrawal & Post-Withdrawal Symptoms" list from the Benzodiazepine Information Coalition website (Benzoinfo.com). The source list in Appendix 1 contains 235 rows, which include spacer lines and occasional duplicate items. For analysis, the wording was lightly standardized (e.g., harmonizing dashes, writing out "and") to ensure consistent mapping to mechanistic axes; these formatting changes did not affect axis counts or phenotype assignments. The questionnaire was completed by all patients at intake.

Rating Scale

As shown in Appendix 1, each item was rated on a 0–10 severity scale (0 = not at all; 10 = most severe). Scores ≥7 were defined as clinically relevant and prioritized for analysis. This threshold was established within this program for two key reasons. First, it aligns with the program's clinical focus on the most severe and impactful complaints; second, it provides a necessary filter to reduce data complexity within this 233-item instrument by identifying the subset of symptoms most likely to be the focus of treatment and most sensitive to meaningful change. Generally, improvement in high-severity symptoms is often accompanied by improvement in less severe items. Throughout this manuscript, symptoms rated ≥7/10 are considered clinically relevant and are referred to as "severe" for simplicity.

PROMIS-29

The PROMIS-29 v2.0 questionnaire was completed at intake by 38 of the 39 patients. It assessed seven domains—Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, and Pain Interference—plus a single Pain Intensity item (0–10). Each domain was scored with four Likert-scale items. Raw scores were converted to T-scores (mean = 50, SD = 10) using standard scoring tables (6). Higher scores reflect a greater symptom burden in negative domains (e.g., Anxiety, Fatigue) and better functioning in positive domains (e.g., Physical Function, Social Roles)

Benzodiazepine and Z-Drug Exposure

At intake, benzodiazepine medications and Z-drugs (non-benzodiazepine hypnotics such as zolpidem, zopiclone, and zaleplon) reported by patients were converted to diazepam-equivalent doses using standard clinical equivalency tables from the *Ashton Manual* (7).

Medical and Substance Use History

Patients completed structured medical and substance use history forms at program entry. Reported comorbidities (summarized in Appendix 3) and substance use (summarized in Appendix 4) were used in a clinical context but were not independently verified.

Data Completeness

All 39 patients completed the 233-item withdrawal symptom questionnaire; PROMIS-29 was completed by 38 patients, the medical history by 38, and the substance use history by 36. Overall, data completeness was high: patients left a median of only 1.3% of questionnaire items unanswered (IQR 0.6–5.0%). Three patients had >60% missing responses but were retained, as phenotype assignment could still be made (see Appendix 6). Given the exploratory nature of this study and the modest sample size, analyses were descriptive only, without inferential statistics.

Mechanistic Axes Framework

The granular data from the 233-item questionnaire enabled analysis of symptom patterns beyond isolated complaints. Five mechanistic axes were specified *a priori* to capture these recurring patterns, with each axis anchored in plausible neurobiological or immunological mechanisms (see Discussion and Table 5 for detailed references) (8–31).

- **Corticotropin-Releasing Hormone (CRH)/Adrenergic axis**: anxiety, insomnia, tachycardia, hypervigilance, sweating.

- **Excitatory/Neuroinflammatory axis (ENI)**: fatigue, brain fog, diffuse pain, sensory hypersensitivity.

- **Autonomic axis**: orthostatic intolerance, palpitations, variable blood pressure or heart rate.

- **Basal Ganglia–Cerebellar (BG/Cer) axis**: tremor, movement abnormalities, cognitive–affective dyscontrol.

- **Mast Cell Activation Syndrome (MCAS)-overlap**: flushing, gastrointestinal reactivity, histamine-related sensitivities.

Symptoms from the 233-item questionnaire were mapped to these five mechanistic axes, with the following item counts: CRH (47), ENI (85), Autonomic (61), BG/Cer (19), and MCAS (21). These mappings provided the basis for phenotype assignment.

Phenotype Assignment

Phenotype assignment was rule-based. For each patient, the number of symptoms rated as severe ($\geq 7/10$) within each mechanistic axis was counted. The mechanistic axis with the highest number of severe symptoms defined the dominant phenotype for that patient. This approach identifies phenotype dominance—the mechanistic pathway most active at baseline. Patients with three or fewer severe symptoms across all axes were classified as Low-symptom, representing individuals with less activation of mechanistic pathways at baseline. When severe-symptom counts were tied across two or more axes, the phenotype was classified as Mixed. Mast-cell–related features were coded separately as MCAS–overlap, which could co-occur with any dominant phenotype and was defined by two or more MCAS symptoms rated $\geq 5/10$ (see Appendix 2 for symptom tiers). This operational definition captured clustering patterns without implying a formal MCAS diagnosis.

Ethics and IRB Approval

This study was determined to be exempt from IRB review by the Institutional Review Board of the Biomedical Research Alliance of New York (BRANY). A full waiver of HIPAA authorization was granted.

Results

Cohort Characteristics

Demographic characteristics for the 38 patients (of 39 enrolled) who provided this information are summarized in Table 1. The cohort had a mean age of 50.6 years (SD 11.3), was predominantly White (89.5%), and had a male majority. Most patients were married (60.5%) and not employed (60.5%) at intake. All 39 patients were included in phenotype determination using

the mechanistic framework described earlier: thirty-seven were initiating a supervised taper, while two were post-taper but remained symptomatic.

Table 1. Cohort demographics (N = 38)

Characteristic	Value
Age at intake, years	Mean 50.6 (SD 11.3), range 21.9–76.3
Sex	Female 16 (42.1%); Male 22 (57.9%)
Race	White 34 (89.5%); Other/Multiracial 4 (10.5%)
Ethnicity	Non-Hispanic 31 (81.6%); Hispanic 4 (10.5%); Missing 3 (7.9%)
Marital status	Married 23 (60.5%); Single 12 (31.6%); Partnered/Other 3 (7.9%)
Employment status	Employed 15 (39.5%); Not employed 23 (60.5%)

Footnotes

[a] Cohort included 39 patients (37 initiating taper, two post-taper).

[b] Race, ethnicity, and employment status were self-reported.

[c] "Not employed" includes retired, disabled, or unemployed.

Benzodiazepine and Z-drug Exposure

As detailed in Table 2, clonazepam was the most common benzodiazepine (30.6%) used, followed by diazepam (25.0%), lorazepam (22.2%), and alprazolam (19.4%). The mean diazepam-equivalent dose was 29.9 mg/day (SD 30.7; median 20.0, IQR 11.5–40.0; range 0.4–160). The mean self-reported duration of use was 9.0 years (SD 8.0; median 7.5, IQR 3.0–13.8; range 0.2–34.0).

Table 2. Benzodiazepine and Z-drug exposure at intake (N = 36)

Characteristic	Value
Benzodiazepine type,	**n (%)**
Clonazepam	11 (30.6)
Diazepam	9 (25.0)
Lorazepam	8 (22.2)
Alprazolam	7 (19.4)
Z-drugs	1 (2.8)
Diazepam-equivalent dose, mg/day	
Mean (SD)	29.9 (30.7)
Median (IQR)	20.0 (11.5–40.0)
Range	0.4–160
Duration of use, years	
Mean (SD)	9.0 (8.0)
Median (IQR)	7.5 (3.0–13.8)
Range	0.2–34.0

Footnotes:

[a] Exposure data available for 36 patients. The total cohort was 39; two post-taper patients and one patient with missing data were excluded.

[b] All daily benzodiazepine and Z-drug doses were converted to diazepam equivalents using the Ashton Manual; for patients on multiple agents, equivalents were summed to yield a total daily dose.

Functional Impairment and Symptom Burden (PROMIS-29)

Functional impairment and symptom burden were evaluated using the PROMIS-29 instrument, completed by 38 of the 39 patients at intake. As shown in Table 3 and illustrated in Figure 1,

patients demonstrated impairment across multiple domains compared with population norms (T-score mean = 50, SD = 10). The highest scores were observed in Anxiety (mean 66.2, SD 6.3) and Fatigue (61.4, SD 7.5), with additional elevations in Sleep Disturbance (58.1, SD 6.9), Depression (56.7, SD 7.1), and Pain Interference (59.2, SD 6.5). Reductions were observed in Physical Function (43.8, SD 6.7) and in Social Roles (46.2, SD 8.0), consistent with substantial functional disability. Reported Pain Intensity scores on the 0–10 scale ranged from 0 to 8.

Table 3. PROMIS-29 outcomes at intake (N = 38)

Domain	Mean ± SD T-score
Anxiety	66.2 ± 6.3
Fatigue	61.4 ± 7.5
Sleep Disturbance	58.1 ± 6.9
Depression	56.7 ± 7.1
Pain Interference	59.2 ± 6.5
Physical Function	43.8 ± 6.7
Social Roles	46.2 ± 8.0
Pain Intensity (0–10 raw)	Reported range: 0–8

Footnotes

[a] PROMIS-29 was completed by 38 of 39 patients; one patient did not complete the instrument.

[b] T-scores are normed to a mean of 50 and a standard deviation of 10 in the general population.

[c] The instrument was administered clinically at intake, not as a research tool.

[d] Pain Intensity is reported on a raw 0–10 numeric rating scale (observed range: 0–8).

Figure 1. PROMIS-29 Outcomes (N = 38)

Phenotype Distribution

Phenotype distributions were derived from the 39 patient responses to the 233-item symptom questionnaire. Each symptom was mapped to a pre-specified mechanistic axis based on its underlying neurobiological and immunological rationale, allowing tallies across the CRH, ENI, Autonomic, and BG/Cer domains. MCAS-related symptoms were tracked separately as a cross-cutting modifier (see Methods).

Phenotypes were assigned using the rule-based algorithm described in Methods, which identified the axis with the highest number of severe ($\geq7/10$) symptoms as dominant. This captured the mechanistic pathway most active at baseline.

The resulting distribution was heterogeneous (Table 4, Figure 2). Most patients (79.5%) clustered into one of three phenotypes: CRH-heavy (35.9%), ENI (33.3%), or Autonomic (10.3%)—while fewer were classified as Low-symptom (17.9%) or Mixed (2.6%). No patients met criteria for a BG/Cer-dominant phenotype. Mixed phenotypes were defined by ties in severe symptom counts across two or more axes, and Low-symptom phenotypes were assigned to patients who endorsed three or fewer severe symptoms in total, distributed across domains without a dominant cluster in any single axis. The absence of BG/Cer phenotypes likely reflects both the rarity of motor-dominant withdrawal presentations and the questionnaire's limited capture of motor features (19 of 233 items). The Low-symptom group highlights that phenotype

definition was based on clusters of the most severe symptoms, rather than capturing the full spectrum of withdrawal-related distress.

Table 4. Phenotype distribution at intake (N = 39)

Phenotype	Count	Percent
CRH-heavy	14	35.9%
Excitatory–Neuroinflammatory (ENI)	13	33.3%
Autonomic	4	10.3%
Basal Ganglia–Cerebellar (BG/Cer)	0	0.0%
Mixed	1	2.6%
Low-symptom	7	17.9%
Total	**39**	**100.0%**

Footnotes:

[a] Severe symptoms were defined as those rated ≥7 on a 0–10 severity scale.

[b] The Low-symptom phenotype was assigned to patients with three or fewer severe symptoms across all axes.

[c] The Mixed phenotype was assigned in cases of a tie in the number of severe symptom counts across two axes.

[d] MCAS-overlap was coded as a cross-cutting modifier and did not define the primary phenotype.

[e] Complete patient-level tallies are provided in Appendix 5.

[f] Abbreviations: CRH = corticotropin-releasing hormone.

Figure 2. Phenotype distribution at intake (N = 39)

MCAS-Overlap
Features consistent with mast cell activation were common across the cohort. As shown in Figure 3, just over half of patients (21/39, 53.8%) met the study's definition of MCAS-overlap, having two or more of 21 mast cell–related symptoms rated ≥5/10 in severity (see Methods). Overlap was most frequent in the Autonomic phenotype (100%, 4/4) and in the ENI phenotype (69.2%, 9/13). Moderate prevalence was observed among CRH-heavy patients (50.0%, 7/14), while representation was limited in the Low-symptom group (14.3%, 1/7). No overlap occurred in the single patient with Mixed phenotype, and no BG/Cer phenotypes were identified. All Autonomic phenotype patients met MCAS criteria, likely reflecting the small size of this subgroup and the frequent co-occurrence of allergic/reactivity features with autonomic dysfunction. MCAS-overlap was treated as a cross-cutting, symptom-based modifier to highlight potential immune reactivity and does not imply a formal diagnosis of mast cell activation syndrome.

Figure 3. MCAS-Overlap Across Phenotypes (N = 39)

Phenotypic Context and Comorbid Conditions

The defined phenotypes presented as clinically distinct yet biologically coherent patterns of withdrawal. CRH-heavy cases were dominated by adrenergic surges, panic-like episodes, insomnia, and persistent hyperarousal consistent with stress-axis overactivation. ENI-dominant presentations featured cognitive fog, sensory hypersensitivity, anhedonia, and fatigue indicative of glutamatergic–microglial dysregulation and neuroinflammatory signaling. Autonomic-dominant patients exhibited orthostatic intolerance, tachycardia, gastrointestinal dysmotility, and temperature instability, reflecting impaired sympathetic–vagal balance. No patients were classified as BG/Cer-dominant, although isolated motor features such as tremor, muscle spasms, and coordination difficulty suggested partial cerebellar or basal-ganglia involvement.

Across the cohort, this mechanistic diversity was mirrored in self-reported comorbidities spanning psychiatric, cardiovascular, metabolic, immune, and autoimmune domains (Appendix 3). Substance use histories are available in Appendix 4.

Collectively, these findings indicate that the observed phenotypes were not statistical artifacts but represent clinically recognizable constellations grounded in plausible neurobiological mechanisms.

Discussion

Summary of Findings

This study characterizes benzodiazepine withdrawal as a set of distinct, mechanistically coherent phenotypes rather than a unitary syndrome.
Among 39 patients, symptom clustering defined three dominant presentations—CRH-heavy, Excitatory–Neuroinflammatory (ENI), and Autonomic—which together accounted for nearly 80% of the cohort. Smaller proportions exhibited Low-symptom (17.9%) or Mixed (2.6%) patterns.

These findings extend descriptive models such as benzodiazepine-induced neurological dysfunction (BIND) [1–2] by proposing a five-axis neurobiological framework that maps withdrawal phenomena onto specific mechanistic pathways. Within this framework, each defined phenotype reflects a distinct pattern of phenotype dominance—the relative predominance of one mechanistic pathway within a broader multi-axis landscape—illustrating how multi-axis interactions give rise to clinical diversity.

Just over half of patients (53.8%) demonstrated MCAS-overlap, suggesting that immune–allergic dysregulation frequently accompanies neurobiological dysregulation in benzodiazepine-related syndromes. This association should be interpreted cautiously, as it reflects a study-specific, symptom-based construct rather than a formal MCAS diagnosis.

Low-symptom presentations further suggest either a milder expression along a continuum or a distinct clinical subtype, emphasizing that axis activation can vary substantially in intensity. Taken together, these findings delineate a structured, biologically grounded model for understanding the heterogeneity of benzodiazepine withdrawal.

Figure 4 provides a schematic representation of this framework, distinguishing fixed mechanistic axes from cross-axis experiential modes—state-dependent phenomena that may dominate clinical presentation without constituting independent mechanistic driver domains. These modes are understood to arise under conditions of combined axis load, which may be produced by shared upstream destabilizing influences (e.g., loss of inhibitory tone, neuroendocrine stress signaling, excitatory burden, autonomic instability, and immune mediator signaling).

Terminology and classification rules
In this model, an axis refers to a mechanistically distinct physiological domain that can meaningfully shape clinical presentation and stabilization priorities. Axes are distinguished from cross-cutting modes or states, which may dominate phenomenology yet remain downstream of axis-level physiology. The Five Axes are proposed as a minimal, irreducible set at the level of mechanistic abstraction used here: collapsing or omitting any axis predictably reduces explanatory coherence and increases category error in clinical interpretation.

Framework architecture and constraints
The five mechanistic axes described here are intended as a fixed organizational scaffold that reflects the dominant domains of neurobiological dysregulation in benzodiazepine withdrawal.

These axes represent mechanistically grounded driver domains rather than symptom groupings and are not intended to expand as additional clinical phenomena are described. Phenomena such as depersonalization/derealization, dissociative perceptual changes, shutdown states, or heightened motor readiness are best understood as modes or states that emerge from interactions among the defined axes—particularly under sustained stress, autonomic instability, or an excitatory–inhibitory imbalance—rather than as independent mechanistic axes.

Figure 4. Mechanistic Axes and Cross-Axis Modes of Expression

Biological Plausibility

This study proposes a mechanistically anchored framework of five neurobiological axes to explain the observed clinical heterogeneity in benzodiazepine withdrawal, positing that the identified phenotypes align with well-established neurobiological pathways. Long-term benzodiazepine exposure enhances $GABA_A$ receptor signaling acutely but drives compensatory neuroadaptations, including altered subunit composition and receptor trafficking (32–36), upregulated glutamatergic transmission (14) and heightened locus coeruleus (LC) norepinephrine output and concurrent CRH–hypothalamic–pituitary–adrenal (HPA) axis activation (8–12). These shifts disinhibit limbic and autonomic circuits, increase central sensitization, and promote

glial and immune reactivity (including astrocyte and microglia-mediated neuroimmune signaling (15,16) and mast cell degranulation (27–30). Collectively, these processes generate a persistent hyperexcitable neurobiological state that shapes phenotype expression during taper, via the core neurobiological pathways:

Core Neurobiological Pathways

- **CRH–Norepinephrine Hyperactivity**: Increased corticotropin-releasing hormone (CRH)-driven locus coeruleus noradrenergic output (8–12,17)

- **Glutamatergic Excitability–Neuroinflammation**: GABAergic disinhibition unleashes glutamatergic transmission, which can manifest as central excitability and, through excitotoxic stress, promote neuroinflammation (13–16)

- **Autonomic Dysregulation**: Characterized by reduced vagal tone, baroreflex alterations, and sympathetic dominance (18–22)

- **Basal Ganglia–Cerebellar Dysfunction**: Region-specific $GABA_A$ dysregulation in motor control circuits (23–26,31)

- **MCAS (modifier)**: Stress-induced CRH signaling can activate mast cells, yielding systemic inflammatory mediator release (27–30)

To demonstrate biological plausibility, the observed clinical phenotypes were mapped onto the pathways:

Phenotype–Pathway Mapping

- **CRH-heavy phenotype** maps onto CRH–Norepinephrine Hyperactivity.

- **Excitatory–Neuroinflammatory (ENI) phenotype** maps onto Glutamatergic Excitability and its downstream effects.

- **Autonomic phenotype** maps onto Autonomic Dysregulation.

- **Basal Ganglia–Cerebellar (BG/Cer) phenotype** maps onto Basal Ganglia–Cerebellar Dysfunction.

- **MCAS features were** analyzed as a modifier rather than a stand-alone phenotype.

- **Mixed and Low-symptom phenotypes** were defined by study-specific threshold rules (see Methods).

The frequent co-occurrence of symptoms across these domains reflects the interconnected nature of neuroimmune pathways. Table 5 integrates these proposed phenotypes with their dominant mechanistic pathways, representative clinical features, and supporting literature.

Table 5. Biological Plausibility of Phenotypes

Phenotype	Dominant Mechanistic Pathway	Representative Clinical Manifestations	Supporting References
CRH-heavy	CRH-driven activation of locus coeruleus (LC) noradrenergic circuits; HPA axis rebound dysregulation	Panic, tachycardia, hypervigilance, intrusive anxiety	(8–12,17)
Excitatory–Neuroinflammatory (ENI)	GABAergic disinhibition → glutamatergic hyperexcitability; NMDA receptor sensitization; microglial activation and cytokine signaling	Insomnia, sensory hypersensitivity, agitation, fatigue, cognitive slowing	(13–16)
Autonomic	LC overactivation with impaired parasympathetic restraint → autonomic instability	Orthostatic intolerance, palpitations, presyncope, GI dysmotility	(18–22)
Basal Ganglia–Cerebellar (BG/Cer)	Region-specific $GABA_A$ receptor adaptations in motor coordination circuits; GABAergic dysfunction in BG–Cerebellar loops	Tremor, dysmetria, ataxia (not dominant in this cohort)	(23–26,31)
Mixed	Co-dominance of ≥2 phenotypes at threshold severity	Hybrid presentations (e.g., CRH + ENI features in same patient)	[Study-defined classification rule]
Low-symptom	≤3 severe symptoms without clustering; minimal activation of mechanistic pathways	Mild or scattered symptoms, often improved with stabilization	[Study-defined classification rule]
MCAS (modifier)	Stress-induced mast cell activation, CRH–mast cell feedback, microglia–mast cell crosstalk	Flushing, chemical sensitivity, GI dysmotility, fatigue (across phenotypes)	(27–30)

Footnotes

Abbreviations: CRH = Corticotropin-Releasing Hormone; ENI = Excitatory–Neuroinflammatory; NMDA = N-methyl-D-aspartate, GI = Gastrointestinal, BG/Cer = Basal Ganglia–Cerebellar; MCAS = Mast Cell Activation Syndrome (an overlap/modifier, not a formal syndrome diagnosis)

Cohort Complexity

The cohort was medically and psychiatrically complex. Most patients reported psychiatric diagnoses—including anxiety, depression, post-traumatic stress disorder (PTSD), and attention-deficit/hyperactivity disorder (ADHD)—alongside substantial systemic comorbidities spanning gastrointestinal, endocrine–metabolic, cardiovascular, and autoimmune disorders. The moderate prevalence of MCAS-overlap features underscores that immune–allergic dysregulation represents a significant dimension of benzodiazepine withdrawal, particularly within Autonomic presentations, where overlap was universal. The frequent co-occurrence of these immune features with Excitatory–Neuroinflammatory (ENI) profiles suggests shared underlying mechanisms and highlights neuroimmune dysregulation as a potential therapeutic target.

Comparison with Prior Work

The identification of distinct, mechanistically coherent phenotypes in benzodiazepine withdrawal extends prior descriptive work—including the *Ashton Manual (7)* and large patient surveys (1,2) —by moving beyond symptom cataloguing to propose a biologically grounded framework of organization. These findings align with reviews describing receptor- and circuit-level adaptations underlying tolerance and withdrawal (3–5) and provide a mechanistic foundation for the individualized approach emphasized in recent tapering guidelines (37–39).

Contemporary deprescribing frameworks often center on pharmacokinetics, particularly the hyperbolic tapering models that emphasize receptor occupancy(40). While valuable for dose modeling, such approaches may not fully capture the neurobiological heterogeneity observed in the present cohort of 39 patients. In practice, however, strict adherence to universal percentage-based tapering frequently failed in those presenting with severe, multifaceted withdrawal, suggesting that pharmacokinetics alone may be insufficient to guide management.

The phenotypic framework developed here offers a complementary, pathophysiological perspective in which stabilization of dysregulated neurobiological systems precedes dose reduction. It implies that, for many patients, the rate of taper may be less consequential than the underlying state of neurobiological dysregulation. For example, a patient with a dominant CRH-heavy phenotype may require extended stabilization to dampen adrenergic hyperarousal before any taper—regardless of reduction size—can be tolerated, whereas a Low-symptom phenotype might accommodate a more direct reduction. Future tapering protocols should therefore integrate phenotype considerations alongside pharmacokinetics, emphasizing stabilization of the dominant mechanistic axes of dysfunction before taper initiation.

Implications and Future Directions

Benzodiazepine withdrawal is best understood not as a transient rebound anxiety state but as a syndrome with identifiable biological phenotypes. By mapping symptom clusters onto plausible neurobiological mechanisms, this study offers a provisional framework that renders withdrawal clinically interpretable for practitioners and actionable for researchers. This shift could move clinical care toward phenotype-targeted support and encourage health systems to recognize withdrawal as a legitimate, heterogeneous condition.

Future research should validate and refine this framework through larger, multisite cohorts with prospective, longitudinal tracking of symptoms and phenotypes. The integration of biomarkers—such as cortisol, cytokines, and heart-rate variability—could objectively validate mechanistic assignments. Neuroimaging, autonomic testing, and immunological assays may provide further biological correlates. Such studies should also examine other neurobiological systems, including monoaminergic pathways (dopamine and serotonin) regulating reward and affect, which may illuminate mechanisms shared with SSRI or antipsychotic withdrawal. Another critical frontier is the gut–brain axis, particularly how microbiome–immune interactions may contribute to systemic manifestations in protracted withdrawal.

Strengths

The strengths of this study include enrollment of consecutive, real-world patients, high data completeness, and integration of a comprehensive symptom inventory with the PROMIS-29, a validated functional measure. These methodological features yielded reproducible symptom patterns consistent with neurobiological plausibility and extended the field beyond prior descriptive work.

Limitations

This study has several limitations. As a single-site, self-pay specialty cohort, the findings may not generalize beyond highly symptomatic patients who can access such care. All data were self-reported without independent verification; medical comorbidities and substance use histories were not adjudicated, introducing potential bias. The 233-item symptom questionnaire, while clinically comprehensive, lacks formal psychometric validation. Estimates of MCAS-overlap prevalence should be interpreted cautiously as they reflect a symptom-based operational threshold rather than a validated diagnostic measure.

Although the five mechanistic axes were pre-specified from established biology, the assignment of phenotype dominance relied on a pragmatic severity threshold ($\geq$7/10) and rule-based tallies in an exploratory analysis. Confirmatory clustering or hypothesis testing was not conducted, and without a control group, causal inference is not possible. Only baseline assessments were analyzed, so phenotypic stability over time remains unknown. Laboratory or biomarker data, when obtained during routine care, were beyond the scope of this analysis. Finally, Mixed presentations indicate that phenotypes are not mutually exclusive, and the proposed axes may not capture all relevant domains of neurobiological dysregulation.

Conclusion

This study demonstrates that benzodiazepine withdrawal is not a single, uniform syndrome but instead clusters into reproducible, biologically grounded phenotypes. Recognizing these constellations helps clinicians anticipate vulnerabilities and tailor management, moving beyond a one-size-fits-all approach. Systematic use of the 233-item symptom questionnaire provides a tool for tracking progress and a framework for guiding individualized, mechanism-based tapering strategies.

It is critical to interpret these phenotypes as indicators of vulnerability rather than fixed trajectories; patients with high-risk profiles may still taper smoothly, while those with low-risk profiles may struggle under stress. Phenotype assignment is based on patient self-report and reflects the perceived symptom burden. Furthermore, a phenotype may remain latent and only emerge under physiological or psychosocial stress. Accordingly, these patterns should be understood as indicators of latent propensities that interact with environmental and lifestyle factors during the tapering process.

Although this analysis focused on benzodiazepines, similar neuroadaptive perturbations occur in withdrawal from SSRIs (41–43), antipsychotics (44), and other psychotropic medications (45). SSRI withdrawal, though rooted in serotonergic rather than GABAergic mechanisms, has been shown to produce reproducible clusters—flu-like malaise, disequilibrium, insomnia, sensory hypersensitivity, and hyperarousal—that correspond to the stress-response axes described here. This convergence suggests that diverse drug classes, despite distinct receptor targets, may perturb common final pathways, making a multidimensional, mechanism-based framework broadly relevant.

By mapping symptom clusters onto plausible neurobiological mechanisms, this work validates patient experience, provides a framework for mechanistic research, and advances the goal of more predictable, safer clinical management of benzodiazepine discontinuation.

List of Abbreviations

BIND = Benzodiazepine-induced neurological dysfunction
BG/Cer = Basal Ganglia–Cerebellar
CRH = Corticotropin-releasing hormone
ENI = Excitatory–Neuroinflammatory
MCAS = Mast Cell Activation Syndrome
PROMIS-29 = Patient-Reported Outcomes Measurement Information System Profile v2.0

Acknowledgements

The author acknowledges the patients whose clinical experiences and questionnaire responses formed the basis of this analysis. My sincere thanks go to Khristine Anne Garcia for her tireless assistance and unwavering support. Her dedicated efforts in patient care and data organization were essential to this study. The author also thanks the Benzodiazepine Information Coalition (Benzoinfo.com) for making available the comprehensive symptom list from which the 233-item withdrawal questionnaire was derived.

Funding

Independent clinical research; no external funding.

Conflicts of Interest

The author declares no conflicts of interest.

Ethics Statement

This study was determined exempt from IRB review by the Institutional Review Board of the Biomedical Research Alliance of New York (BRANY). A full waiver of HIPAA authorization was also granted.

Data Availability

De-identified data underlying this manuscript are available from the corresponding author on reasonable request.

References:

1. Finlayson A, Macoubrie J, Huff C, Foster D, Martin P. Experiences with benzodiazepine use, tapering, and discontinuation: an internet survey. Ther Adv Psychopharmacol. 2022;12:20451253221082386.
2. Huff C, Finlayson A, Foster D, Martin P. Enduring neurological sequelae of benzodiazepine use: an internet survey. Ther Adv Psychopharmacol. 2023;13:20451253221145561.
3. Tan KR, Rudolph U, Lüscher C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci. 2011;34(4):188–97.
4. Vinkers C, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABAA receptor modulators? Adv Pharmacol Sci. 2012;2012:416864.
5. Lorenz-Guertin JM, Povysheva N, Chapman CA, MacDonald ML, Fazzari M, Nigam A, et al. Inhibitory and excitatory synaptic neuroadaptations in the diazepam tolerant brain. Neurobiol Dis. 2023;185:106248.
6. HealthMeasures. PROMIS Adult Profile Instruments: Scoring Manual [Internet]. HealthMeasures; 2025 July [cited 2025 Sept 5]. Available from: https://www.healthmeasures.net/images/PROMIS/manuals/Scoring_Manual_Only/PROMIS_Adult_Profile_Scoring_Manual_15July2025.pdf
7. Ashton H. Benzodiazepines: how they work and how to withdraw. Newcastle upon Tyne, UK: Newcastle University; 2002.
8. Jedema HP, Grace AA. Corticotropin-releasing hormone directly activates noradrenergic neurons of the locus coeruleus recorded in vitro. J Neurosci. 2004;24(43):9703–13.
9. McCall JG, Al-Hasani R, Siuda ER, Hong DY, Norris AJ, Ford CP, et al. CRH engagement of the locus coeruleus noradrenergic system mediates stress-induced anxiety. Neuron. 2015;87(3):605–20.
10. Koob GF. Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry. 1999;46(9):1167–80.
11. Skelton KH, Nemeroff CB, Owens MJ. Spontaneous withdrawal from the triazolobenzodiazepine alprazolam increases cortical corticotropin-releasing factor mRNA expression. J Neurosci. 2004;24(42):9303–12.
12. Wichniak A, Brunner H, Ising M, Pedrosa Gil F, Holsboer F, Friess E. Impaired hypothalamic-pituitary-adrenocortical (HPA) system is related to severity of benzodiazepine withdrawal in patients with depression. Psychoneuroendocrinology. 2004;29(9):1101–8.
13. Casasola C, Montiel T, Calixto E, Brailowsky S. Hyperexcitability induced by GABA withdrawal facilitates hippocampal long-term potentiation. Neuroscience. 2004;126(1):163–71.
14. Van Sickle BJ, Cox AS, Schak K, John Greenfield L, Tietz EI. Chronic benzodiazepine administration alters hippocampal CA1 neuron excitability: NMDA receptor function and expression. Neuropharmacology. 2002;43(4):595–606.
15. Dong Y, Benveniste EN. Immune function of astrocytes. Glia. 2001;36(2):180–90.
16. Raghunatha P, Vosoughi A, Kauppinen TM, Jackson MF. Microglial NMDA receptors drive pro-inflammatory responses via PARP-1/TRMP2 signaling. Glia. 2020;68(7):1421–34.
17. Heberlein A, Bleich S, Kornhuber J, Hillemacher T. Neuroendocrine pathways in benzodiazepine dependence: new targets for research and therapy. Hum Psychopharmacol. 2008;23(3):171–81.

18. Murase S, Inui K, Nosaka S. Baroreceptor inhibition of the locus coeruleus noradrenergic neurons. Neuroscience. 1994;61(3):635–43.

19. Schrezenmaier C, Singer W, Swift NM, Sletten D, Tanabe J, Low PA. Adrenergic and vagal baroreflex sensitivity in autonomic failure. Arch Neurol. 2007;64(3):381–6.

20. Ross JA, Van Bockstaele EJ. The Locus Coeruleus-Norepinephrine System in Stress and Arousal: Unraveling Historical, Current, and Future Perspectives. Front Psychiatry. 2021;11:601519.

21. Thayer JF, Lane RD. Claude Bernard and the heart–brain connection: further elaboration of a model of neurovisceral integration. Neurosci Biobehav Rev. 2009;33(2):81–8.

22. Goldstein DS. Differential responses of components of the autonomic nervous system. In: Mathias CJ, Bannister R, editors. Handbook of Clinical Neurology Vol 117. Amsterdam: Elsevier; 2013. p. 13–22.

23. Galvan A, Wichmann T. GABAergic circuits in the basal ganglia and movement disorders. In: Progress in Brain Research Vol 160. Amsterdam: Elsevier; 2007. p. 287–312.

24. Kralic JE, Criswell HE, Osterman JL, O'Buckley TK, Wilkie ME, Matthews DB, et al. Genetic essential tremor in GABAA receptor α1 subunit knockout mice. J Clin Invest. 2005;115(3):774–9.

25. Fritschy JM, Mohler H. GABAA-receptor heterogeneity in the adult rat brain: Differential regional and cellular distribution of seven major subunits. J Comp Neurol. 1995;359(1):154–94.

26. Hernandez-Martin E, Vidmark JSL, MacLean JA, Sanger TD. What is the effect of benzodiazepines on deep brain activity? A study in pediatric patients with dystonia. Front Neurol. 2023;14:1215572.

27. Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25(11):563–8.

28. Kempuraj D, Papadopoulou NG, Lytinas M, Huang M, Kandere-Grzybowska K, Madhappan B, et al. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology. 2004;145(1):43–8.

29. Forsythe P. Mast Cells in Neuroimmune Interactions. Trends Neurosci. 2019;42(1):43–55.

30. Ayyadurai S, Gibson AJ, D'Costa S, Overman EL, Sommerville LJ, Poopal AC, et al. Frontline Science: Corticotropin-releasing factor receptor subtype 1 is a critical modulator of mast cell degranulation and stress-induced pathophysiology. J Leukoc Biol. 2017;102(6):1299–312.

31. Goetz T, Arslan A, Wisden W, Wulff P. GABAA receptors: structure and function in the basal ganglia. In: Progress in Brain Research Vol 160. Amsterdam: Elsevier; 2007. p. 21–41.

32. Jacob TC, Moss SJ, Jurd R. GABAA receptor trafficking and its role in the dynamic modulation of neuronal inhibition. Nat Rev Neurosci. 2008;9(5):331–43.

33. Gravielle MC. Activation-induced regulation of GABAA receptors: Is there a link with the molecular basis of benzodiazepine tolerance? Pharmacol Res. 2016;109:92–100.

34. Engin E. GABAA receptor subtypes and benzodiazepine use, misuse, and abuse. Front Psychiatry. 2023;13:1060949.

35. Goldschen-Ohm MP. Benzodiazepine modulation of GABAA receptors: a mechanistic perspective. Biomolecules. 2022;12(12):1784.

36. Yoon BE, Jo S, Woo J, Lee JH, Kim T, Kim D, et al. The amount of astrocytic GABA positively correlates with the degree of tonic inhibition in hippocampal CA1 and cerebellum. Mol Brain. 2011;4(1):42.
37. Brunner E, Chen CYA, Klein T, Maust DT, Mazer-Amirshahi M, Mecca M, et al. Joint clinical practice guideline on benzodiazepine tapering: considerations when risks outweigh benefits. J Gen Intern Med. 2025;40(12):2814–59.
38. Brunner EA, Boyle MP, Maust DT. New benzodiazepine tapering guide—slow and patient-centered. JAMA. 2025;334(7):567–8.
39. Brandt J, Bressi J, Lê ML, Neal D, Cadogan C, Witt-Doerring J, et al. Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review. eClinicalMedicine. 2024;70:102507.
40. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6(6):538–46.
41. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf. 2001;24(3):183–97.
42. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84(2):72–81.
43. Gabriel M, Sharma V. Antidepressant discontinuation syndrome. CMAJ. 2017;189(21):E747.
44. Brandt L, Bschor T, Henssler J, Müller M, Hasan A, Heinz A, et al. Antipsychotic withdrawal symptoms: a systematic review and meta-analysis. Front Psychiatry. 2020;11:569912.
45. Vinkers CH, Kupka RW, Penninx BW, Ruhé HG, van Gaalen JM, van Haaren PCF, et al. Discontinuation of psychotropic medication: a synthesis of evidence across medication classes. Mol Psychiatry. 2024;29(8):2575–86.

Figure Legends

Figure 1. PROMIS-29 T-scores at intake (N = 38)
Scores are reported as T-scores (mean 50, SD 10). Higher scores reflect greater symptom burden for negative domains (e.g., Anxiety, Depression, Fatigue, Sleep Disturbance, Pain Interference, Pain Intensity), whereas lower scores indicate greater impairment for positive domains (Physical Function, Social Roles).

Figure 2. Phenotype distribution at intake (N = 39)
Cohort allocation across mechanistic phenotypes showed the following distribution. Counts and percentages are shown within the figure; no patients met criteria for a Basal Ganglia–Cerebellar (BG/Cer) phenotype. Each color segment represents a primary mechanistic axis serving as the patient's dominant phenotype (i.e., reflecting phenotype dominance).

Figure 3. MCAS-overlap across phenotypes (N = 39)
Just over half of patients (21/39, 53.8%) met criteria for MCAS-overlap, defined as two or more of 21 mast cell–related symptoms rated ≥5/10 in severity. Overlap was most frequent in the Autonomic phenotype (100%, 4/4) and ENI phenotype (69.2%, 9/13), with moderate prevalence in CRH-heavy patients (50.0%, 7/14) and limited representation in the Low-symptom group (14.3%, 1/7). No overlap was observed in the single Mixed case, and no BG/Cer phenotypes were identified. MCAS-overlap is presented here as a symptom-based modifier to highlight immune-allergic contributions and does not represent a formal diagnosis of mast cell activation syndrome.

Figure 4. Mechanistic axes and cross-axis modes of expression.
The five axes represent mechanistically distinct domains of neurobiological dysregulation in benzodiazepine withdrawal. Prominent experiential phenomena (e.g., depersonalization/derealization, threat vigilance/hyperarousal, shutdown/hypoarousal, motor activation/akathisia-like states) are conceptualized as emergent, state-dependent modes that arise under conditions of combined axis load and loss of inhibitory control. Although these modes may dominate clinical presentation, they are not classified as axes because they do not represent independent mechanistic driver domains. Shared upstream destabilizing influences may load multiple axes simultaneously, contributing to cross-axis modes of expression.

Appendix 1. Benzodiazepine Withdrawal Symptom Questionnaire (Full)

Symptom	Severity (0–10 scale)
Abdomen Cramping & Distention	
Achiness	
Aching jaw	
Aching joints	
Aching muscles	
Acute hyperexcited state	
Aggressive behaviour	
Agitation	
Agitated sight	
Agoraphobia	
Air Hunger	
Akathisia	
Allergic reactions	
Allergic reactions to/Intolerance of foods previously tolerated	
Allergy & nasal symptoms exacerbated	
Anger	
Anhedonia	
Anorgasmia	
Anxiety	
Apathy	
Appetite – either loss of, or voracious appetite with constant desire to eat	
Arms and legs feel detached from body	
Ataxia	
Band around head	
Bladder Incontinence	
Bleeding between menstrual cycles	
Bleeding from the nose	
Blepharospasm	
Blood Pressure Issues (High or Low)	
Blurred Vision	
Body Temperature Fluctuations	
Brain Fog	
Body odor	
Bradycardia	
Brain moving within the skull sensation	
Breasts (heavy, over-sensitive, swollen, enlarged, painful)	
Breathing difficulties	
Breathlessness	
Bruxism	

Buildings appear to be leaning	
Burning along the spine	
Burning Sensations on Skin	
Buzzing, burning, tingling limbs	
Changes in perception (faces distorting and inanimate objects moving)	
Changes in skin color, tone, texture	
Chemical Sensitivities	
Chest tightness	
Chills	
Choking	
Claustrophobia	
Clumsiness	
Cognitive impairment	
Confusion	
Constipation	
Cracked and sore lips	
Cramping in stomach	
Cramping of the muscles	
Craving for sweets and sugary foods	
Crying Spells	
Cuts and abrasions taking weeks to heal	
Dark circles under eyes	
Decaying teeth and gums	
Dehydration	
Delirium	
Demented and murderous thoughts	
Dental Pain	
Depersonalization	
Depression	
Diarrhea	
Difficulty swallowing	
Disorientation	
Dizziness	
Double Vision	
Dry Retching	
Dry throat, sore tongue, and thrush	
Dyspepsia	
Dysphagia (difficulty eating or swallowing)	
Dysphoria (inability to feel pleasure or happiness)	
Dyspnea (breathing difficulty)	
Dystonia	
Earache and sinus problems	

Edema	
Electronic Zaps	
Emotional Blunting	
Epileptic Fits	
Esophageal Spasms	
Esophagitis	
Excitability	
Exhaustion	
Extreme cold	
Extreme thirst	
Eyes – sore, tired, seeing floaters, spots, itchy, red	
Eye Dryness	
Facial Numbness	
Fear (terror)	
Feeling of extreme heat or cold	
Feeling of impending doom	
Feelings of shaking inside and out	
Feeling of shame	
Feelings of unreality	
Feelings of worms under scalp	
Female ejaculation or incontinence during orgasm	
Fingernail problems – median nail dystrophy (line/ridge down the centre), ridges	
Flashbacks	
Fluctuations in blood pressure	
Flu-like symptoms (“Benzo flu”)	
Flushing	
Formication	
Fuzzy feeling in head	
Gait Abnormality	
Gastritis	
Glassy eyes	
Goosebumps – very visible to the eye	
Grinding teeth	
Hair Changes (loss, thinning, dullness)	
Hallucinations	
Headaches	
Heartburn	
Heavy arms and legs	
Hemorrhoids	
Holding onto the walls in the shower	
Hypersensitive Senses	

Heart Palpitations	
Hormonal Imbalances	
Hot Flashes	
Hurts to wear clothes, a car seatbelt	
Hypersensitive (unable to watch the news, see films, read the newspaper)	
Hyperactivity	
Hyperacusis (profound hearing sensitivity, hurts to talk on the phone, music, etc.)	
Hypersomia (sensitive sense of smell)	
Hyperreflexia ('jumpiness')	
Hypersensitivity to being touched	
Hypersensitivity to light, sound, and other stimuli	
Hypersensitivity to stress	
Hypertension (elevated blood pressure)	
Hyperventilation (over breathing)	
Hypnologic (hallucinations, sleepwalking)	
Hysterical and inappropriate laughter	
IBS – irritable bowel syndrome	
Impacted bowels	
Impairment of motor coordination	
Impotence	
Inability to comprehend the simplest things	
Inability to concentrate	
Inability to cope with a lot of information	
Inability to draw a satisfying breath	
Inability to make a decision	
Inability to read or write	
Incontinence, frequent or urgent need to urinate, unable to hold or pass urine	
Increased saliva	
Indigestion	
Insomnia	
Intense fuzzy feeling in the head	
Intense jaw pain	
Intrusive Thoughts	
Iris in eyes changes color	
Irrational rage	
Irrationality (in general)	
Irritability	
Jaundice	
Jaw, tooth, neck and shoulder aches and pains	

Jaw tension, clenching, teeth grinding	
"Jelly Legs" – weakness in the legs	
Jerks in arms, legs fingers	
Joint aches and pains	
Joylessness	
Jumpiness	
Lack of concentration	
Lack of coordination	
Left/Right-sided symptoms	
Legs arms and head very heavy	
Leukonychia (whitening of nails)	
Libidinal changes – variances in sex drive	
Loss of balance	
Loss of concentration	
Loss of confidence	
Loss of control of movement	
Loss of interest in people and/or things	
Loss of memory (short and/or long-term)	
Loss of self respect	
Loss of taste or metallic taste (or other strange tastes)	
Loss or changes in appetite	
Lung pain	
Memory Problems	
Menstrual Problems	
Metallic Taste	
Mood swings	
Muscle aches	
Muscle spasms	
Muscle weakness	
Nausea	
Nervousness	
Nightmares	
Night sweats	
Numbness/Tingling	
Obsessions and obsessive behavior, OCD	
Orgasm changes	
Outbursts of aggression and rage	
Pain	
Painful scalp	
Panic Attacks	
Paresthesia	
Paranoia	
Parosmia	
Perception Distortion	

Passing gas continually	
Phobias	
Post Traumatic Stress symptoms	
Postural orthostatic tachycardia syndrome (POTS)	
Premature menopause	
Pseudobulbar / PBA (uncontrollable crying or laugh)	
Psychotic symptoms	
Racing Thoughts	
Rapid blinking of the eyes	
Rapid weight loss	
Rashes on skin	
Reading/Comprehension Problems	
Repetitive Thoughts	
Restless Legs	
Scalp Pain	
Shivering	
Sinusitis	
Speech difficulties	
Swallowing difficulties	
Tachycardia	
Teeth Pain	
Thyroid disturbances	
Ticking	
Tinnitus	
Toxic naps	
Tremor	
Twitching	
Urinary Problems	
Vertigo	
Visual disturbances – waves, sparks, flashes of light, seeing spots, floaters, blurry	
Vomiting	
Weakness	
Weight Gain or Loss	
Zaps	

Footnotes

[a] Patients rated each symptom for severity on a 0–10 numeric scale.

[b] This questionnaire was administered clinically; it is not a psychometrically validated research tool.

[c] Four symptoms—burping, catatonia, muscle rigidity, and muscle stiffness—are listed on the current Benzoinfo.com symptom inventory (accessed 2025) but are not included here. These differences may reflect later additions or version discrepancies between the 2023 source list and the present version.

Appendix 2. MCAS-overlap Symptom Tiers

Tier	Number of symptoms	% Patients (N = 39)
Tier 1 – Hallmark	5	35.9%
Tier 2 – Supportive	12	53.8%
Tier 3 – Peripheral	4	28.2%

Footnotes

[a] Percentages reflect patients with ≥2 symptoms in a tier rated ≥5/10 in severity.

[b] Tiers are not mutually exclusive; a single patient may meet criteria for more than one tier.

[c] MCAS-overlap refers to a symptom-based modifier and does not represent a formal MCAS diagnosis.

Symptom lists (from the 233-item symptom questionnaire**)**
• Tier 1 – Hallmark (5): Allergic reactions; Allergic reactions to/Intolerance of foods previously tolerated; Allergy and nasal symptoms exacerbated; Flushing; Sinusitis.
• Tier 2 – Supportive (12): Rashes on skin; Chemical sensitivities; Gastritis; Bleeding from the nose; Changes in skin color, tone, texture; Dark circles under eyes; Cuts and abrasions taking weeks to heal; Decaying teeth and gums; Earache and sinus problems; Goosebumps (very visible); Hair changes (loss, thinning, dullness); Fingernail problems (median nail dystrophy, ridges).
• Tier 3 – Peripheral (4): Body temperature fluctuations; Feeling of extreme heat or cold; Feelings of worms under scalp; Formication.

Appendix 3. Medical Comorbidities (Self-Reported)

Category	N (out of 38)	Percent (%)
Psychiatric / Mental Health	38	100.0
Neurological	27	71.1
Endocrine / Metabolic	24	63.2
Immune / Autoimmune	22	57.9
Respiratory	20	52.6
Gastrointestinal	22	57.9
Cardiovascular	19	50.0
Musculoskeletal	21	55.3

Appendix 4. Substance Use History at Intake

Substance	Current n (%)	Past n (%)	Never n (%)
Benzodiazepines	34 (94.4%)	2 (5.6%)	0 (0.0%)
Alcohol	9 (25.0%)	12 (33.3%)	15 (41.7%)
Tobacco/Nicotine	8 (22.2%)	14 (38.9%)	14 (38.9%)
Cannabis	8 (22.2%)	12 (33.3%)	16 (44.4%)
Opioids	4 (11.1%)	3 (8.3%)	29 (80.6%)
Stimulants	2 (5.6%)	5 (13.9%)	29 (80.6%)
Food/sugar	11 (30.6%)	14 (38.9%)	11 (30.6%)

Footnotes

[a] Any reported current use—regardless of frequency or quantity, including occasional use—was coded as "current."
[b] Data were available for 36 of 39 patients; three (BenzoQ36, BenzoQ30, BenzoQ34) did not provide this information.

Appendix 5. Patient-Level Phenotype Tallies (N = 39)

Patient ID	CRH	ENI	Autonomic	BG–Cer	Total severity (≥7/10)	Dominant phenotype	MCAS severity count (≥5/10)	MCAS-overlap
BenzoQ01	21	22	8	2	53	ENI	6	Yes
BenzoQ02	11	7	12	3	33	Autonomic	3	Yes
BenzoQ03	3	4	8	1	16	Autonomic	11	Yes
BenzoQ04	9	12	3	0	24	ENI	9	Yes
BenzoQ05	4	5	0	0	9	ENI	5	Yes
BenzoQ06	1	0	0	0	1	Low-symptom	0	No
BenzoQ07	1	1	0	0	2	Low-symptom	0	No
BenzoQ08	22	21	4	2	49	CRH	1	No
BenzoQ09	0	0	0	0	0	Low-symptom	0	No
BenzoQ10	34	57	32	7	130	ENI	12	Yes
BenzoQ11	4	2	0	0	6	CRH	1	No
BenzoQ12	11	16	9	3	39	ENI	1	No
BenzoQ13	13	7	3	1	24	CRH	2	Yes
BenzoQ14	1	0	0	0	1	Low-symptom	1	No
BenzoQ15	9	8	2	2	21	CRH	2	Yes
BenzoQ16	1	1	0	0	2	Low-symptom	0	No
BenzoQ17	23	18	25	4	70	Autonomic	10	Yes
BenzoQ18	2	0	0	0	2	Low-symptom	0	No
BenzoQ19	11	3	1	1	16	CRH	0	No
BenzoQ20	1	1	1	0	3	Low-symptom	2	Yes
BenzoQ21	19	11	7	1	38	CRH	6	Yes
BenzoQ22	2	5	1	0	8	ENI	1	No
BenzoQ23	21	18	15	2	56	CRH	7	Yes
BenzoQ24	11	4	1	1	17	CRH	1	No
BenzoQ25	1	3	0	0	4	ENI	0	No
BenzoQ26	11	22	12	4	49	ENI	8	Yes
BenzoQ27	3	1	0	0	4	CRH	0	No
BenzoQ28	15	9	3	1	28	CRH	3	Yes
BenzoQ29	4	5	3	0	12	ENI	1	No
BenzoQ30	14	18	1	0	33	ENI	2	Yes
BenzoQ31	16	27	3	7	53	ENI	5	Yes
BenzoQ32	11	15	16	2	44	Autonomic	6	Yes
BenzoQ33	4	3	2	4	13	Mixed	0	No
BenzoQ34	14	8	4	3	29	CRH	1	No

Patient ID	CRH	ENI	Autonomic	BG–Cer	Total severity (≥7/10)	Dominant phenotype	MCAS severity count (≥5/10)	MCAS-overlap
BenzoQ35	4	3	1	0	8	CRH	0	No
BenzoQ36	32	37	14	8	91	ENI	9	Yes
BenzoQ37	2	7	2	1	12	ENI	3	Yes
BenzoQ38	16	4	2	1	23	CRH	5	Yes
BenzoQ39	17	10	7	5	39	CRH	4	Yes

Footnotes:

[a] Phenotypes assigned from the 233-symptom questionnaire (N = 39); primary axis defined by the highest number of severe symptoms (≥7/10).

[b] Mixed = comparable severe counts across ≥2 axes; Low-symptom = ≤3 severe symptoms overall.

[c] MCAS-overlap coded independently as a modifier, based on ≥2 of 21 MCAS symptoms rated ≥5/10.

[d] Patient identifiers shown as BenzoQ codes only.

[e] Abbreviations: CRH = Corticotropin-Releasing Hormone; ENI = Excitatory–Neuroinflammatory; BG/Cer = Basal Ganglia/Cerebellar; MCAS = Mast Cell Activation Syndrome.

Appendix 6. Data Completeness at Intake

Instrument	Completed (n)	Missing (n)	Notes
233-symptom questionnaire	39 (100%)	0	Completed by all 39 patients
PROMIS-29	38 (97.4%)	1	Missing for BenzoQ36
Substance use history	36 (92.3%)	3	Missing for BenzoQ36, BenzoQ30, BenzoQ34
Medical history	38 (97.4%)	1	Missing for BenzoQ35
Phenotype assignment	39 (100%)	0	Derived from 233-symptom questionnaire

Footnote:

[a] This appendix summarizes patient inclusion and instrument completeness.

[b] Patient identifiers are anonymized as BenzoQ codes.

[c] Missing data reflect non-completion of forms.

[d] Although all 39 patients completed the 233-item questionnaire, the median proportion of unanswered items was 1.3% (see Methods).